Lichen International heads into its April 30 earnings report after one of the sharpest single-week selloffs the stock has seen — down 38% in seven days to $4.00, with a 27% decline on Tuesday alone.
The price collapse is the dominant story here, and the borrowing market is not the driver. Availability in the lending pool is extraordinarily loose — over 4,100% of short interest, meaning shares are easily available to borrow relative to the current short position. Cost to borrow has risen about 72% over the past month to roughly 24%, which sounds elevated but is consistent with LICN's status as a micro-cap Nasdaq-listed name. Short interest itself is minimal at just 0.084% of free float — a figure that has actually fallen 38% on the week. There is no meaningful short position being built into this print.
The borrow activity and the ORTEX short score — currently 45, down from a peak above 51 earlier in the month — tell the same story: shorts have been retreating, not accumulating. The lending market peaked in early April, when availability was far tighter, cost to borrow was climbing, and utilization reached a 52-week high of 86%. That pressure has since unwound. Utilization is now at roughly 24%, compared to readings above 75% in late March and early April. The borrow squeeze, if there was one, has already passed.
The question the earnings report must answer is more fundamental. A research and consulting services company with a sub-$90 million market cap has lost a third of its value in a single month without any obvious catalyst visible in the short interest data. Correlated US peers like and fell 6–7% on the week — significant, but a fraction of LICN's move. That divergence suggests the selloff is stock-specific rather than sector-driven. Past earnings reactions have been mixed: the December 2025 print produced a 1-day drop of nearly 8%, while the September 2024 release saw a modest 4% gain on the day before giving back ground over five sessions.
Tomorrow's release is therefore a test of whether the fundamentals justify a stock now trading at $4.00 — and whether management can offer any explanation for the gap between LICN's performance and that of its consulting-sector peers.
See the live data behind this article on ORTEX.
Open LICN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
